University of Cambridge, Cambridge, UK Email: lsin4@student.monash.edu Background: Children born extremely preterm (EP; ≤28 weeks gestation or <1000 g) have elevated rates of working memory difficulties that contribute to their academic underachievement. While working memory training has shown promise in this population, there is little evidence to support long-term training benefits, particularly for academic functioning and using rigorous study design methodologies. This randomised controlled trial aimed to assess the effectiveness of a computerised working memory training program (Cogmed) in improving 1) long-term academic functioning two years post-training and 2) short-and long-term working memory and attention skills, compared with a placebo program in EP 7-year-olds.
Methods: Ninety-one EP 7-year-old children were randomised to either Cogmed or the placebo program (1:1 ratio), and underwent intensive, computerised training in the home for 5-7 weeks. Assessment of academic functioning, working memory, attention and behaviour were conducted prior to training (baseline) and at 2 weeks, 1 year and 2 years post-training.
Results: Using mixed-effects regression models, there was little evidence for a Cogmed benefit in academic outcomes 2 years post-training, or at earlier time-points compared with the placebo group. Similarly, there was little evidence of a treatment effect for working memory, attention or behavioural outcomes at all follow-up time points.
Conclusions: There is little benefit of working memory training for working memory or academic outcomes in EP children at early school-age. Background: Preterm birth is the largest contributor to neonatal mortality and morbidity worldwide, and is strongly linked with in-utero inflammation/chorioamnionitis. Infants born preterm, and with chorioamnionitis, are at high risk of white matter brain injury and long-term neurological impairment, like cerebral palsy. An immunomodulatory therapy would be an optimal treatment strategy. This study aimed to assess the efficacy of mesenchymal stem cells (MSCs) in a large animal model of inflammation-induced brain injury.
MESENCHYMAL STEM CELLS MODULATE BRAIN INFLAMMATION AFTER LPS ADMINISTRATION IN
Methods: Chronically instrumented fetal sheep at 0.65 gestation were administered IV LPS (150 ng, 055:B5) or saline for controls, over 3 consecutive days. Stem cell treated animals received IV 10 million human umbilical cord MSCs, 6 hours after the final LPS dose. Seven days later, CSF was collected, and brains processed for histological analysis of subcortical and periventricular white matter (SCWM & PVWM) .
Results: Neuroinflammation and cell death were evident within the brains of LPS-treated animals with significant increases in lectin aggregates and caspase-3 in SCWM and PVWM, together with IL1β elevation in CSF. LPS reduced oligodendrocyte counts (Olig-2 and MBP) in the PVWM and SCWM. MSC treatment prevented the increase in IL1β, and significantly increased levels of IL10 in the CSF. MSC treatment attenuated cell death and lectin aggregation, but did not recover the loss of total and mature oligodendrocytes.
Conclusions: MSCs protected the preterm brain against inflammation and cell death but did not rescue the loss of myelinating oligodendrocytes. Given the white matter is not protected by MSCs, future studies may investigate combining MSCs with a cell therapy that can initiate white matter repair.
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